Aziyo Biologics launches bone matrix for orthopedic surgery

Alan Condon -   Print  |

Regenerative medicine company Aziyo Biologics on June 29 launched OsteoGro V, a viable cell bone matrix to assist with bone repair.

Three things to know:

1. OsteoGro V features cancellous bone particles and demineralized cortical bone particles and fibers to improve product handling.

2. Aziyo Biologics has entered into several private-label distribution agreements, which is expected to boost adoption in the spine, orthopedic and dental markets. 

3. Founded in 2015, Aziyo Biologics' products focus on improving outcomes in implantable device- related complications.

© Copyright ASC COMMUNICATIONS 2021. Interested in LINKING to or REPRINTING this content? View our policies here.

Featured Webinars

Featured Whitepapers